NAFLD was confirmed by liver enzymes, and the HFD group revealed higher serum activities of transaminases ALT and AST compared to the HFD + AICAR group (Figure 1D; p < 0.001, p = 0.0004, respectively). The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.